Everything tagged "growth" across research, earnings, and macro.
192 articles
Citigroup is evolving from a restructuring story into a stronger global banking franchise, with Services and Markets driving better growth, leverage, and returns. The stock still trades at a reasonable valuation despite clear operating momentum.
Goldman Sachs is pairing record capital-markets results with a growing wealth and asset-management mix. The stock looks attractive for investors who want a high-quality financial franchise, though valuation keeps the upside measured.
Flex is shifting toward higher-value manufacturing, with Cloud and Power Infrastructure driving growth and a planned spin-off in 2027. Stronger margins and upbeat fiscal 2027 guidance support a Buy case, though the stock is no longer cheap.
MongoDB’s 5.7% drop looks disconnected from what the business is actually doing. Atlas is still growing above 29%, AI retrieval just expanded beyond Atlas, and that makes this look more like a reset in sentiment than a break in the story.
KB Financial Group is pairing record fee income growth with aggressive capital returns, including a dividend hike and a large buyback-and-cancel plan. The stock still looks reasonably valued versus its earnings momentum and diversified earnings mix.
TSMC looks like the market's next real AI stress test, and the setup still leans bullish into July 16. When a company is growing revenue 33% with 61.9% gross margins and Wall Street is pressing for higher 2026 expectations, the earnings bar is high for a reason.
Alnylam just got the kind of competitive win biotech investors rarely get handed this cleanly: a rival late-stage ATTR-CM miss after AMVUTTRA already secured the label and commercial traction. With revenue up 65.2% year over year and AMVUTTRA driving more than $1 billion in quarterly product revenue, the stock still looks like the clearest winner in a narrowing field.
Ionis got hit as if the Wainua trial miss broke the whole equity story, and that looks too simplistic. The bigger near-term driver is now TRYNGOLZA's expanded launch, with commercial revenue already up 42% and management raising its olezarsen peak-sales view above $3 billion.
Vodafone is a medium-term turnaround story with improving revenue, EBITDAaL, and free cash flow, but Germany weakness and heavy debt keep the risk profile elevated. The stock looks attractive only if execution continues and valuation leaves room for setbacks.
Dell’s AI server surge, strong backlog, and improving PC refresh are driving a sharp earnings reset. The stock earns a Buy as the business scales faster than its old hardware reputation suggests.
PepsiCo is showing real operating momentum, with Q1 2026 revenue up 8.5% and management reaffirming 2026 growth guidance. The stock looks like a Buy on weakness, supported by strong brands, improving volumes, and a reasonable valuation.
Ionis is evolving into a multi-product commercial RNA medicines company, with TRYNGOLZA and DAWNZERA driving real revenue growth and a larger market opportunity now open for TRYNGOLZA.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the Generator